The LiliumX™ Platform
Rethinking ADCs
Bispecific and multispecific ADCs are complex molecules. Finding the right combination of targets, binders, formats, and payloads is hard. At Valink, we combine protein engineering, synthetic biology, automation, and AI to unlock the full potential of ADCs.
Exploring every possibility
Our modular high-throughput screening platform, LiliumX™, enables us to break down each ADC into its building blocks, giving us true modularity. These components are then mixed-and-matched to generate a very broad diversity of possible bispecific ADCs with different combinations of targets, binders, formats, linkers and payloads. We test all the permutations, to reveal the combinations with the highest potential.
Redefining efficacy
We go beyond conventional binary gating with our V-Gate approach, enabling more dynamic effects that redefine what bispecific ADCs can achieve. The result is better delivery of drugs to the target cells, opening the door to more effective and safer medicines.
Designing with data
Combined with curated disease datasets, we are developing AI models that can reveal powerful, unexpected synergies across targets and components –informing our molecular design and ultimately patient response of our unique bispecific ADC designs.
A passion for Protein Engineering
Valink has developed and continues to invent novel technologies across protein engineering. Beyond bispecific ADCs, we are developing novel approaches for dual payload conjugation, trispecific ADC design, and multivalent antibody platforms – even multivalent agonists. We push the boundaries of what is possible with proteins.
Work with Valink
To discuss potential collaborations, reach out via LinkedIn or connect@valinktx.com; to join our team in the US or UK, visit our Careers Page.
Contact us
Valink Therapeutics Inc
One Broadway,
Cambridge,
Massachusetts,
02142
Valink Therapeutics Ltd
Imperial I-Hub,
84 Wood Lane,
London,
W12 0BZ